PortalPublikationenImpact of ABO blood type on outcomes in patients with primar...

Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer

Standard

Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. / Klatte, Tobias; Xylinas, Evanguelos; Rieken, Malte; Kluth, Luis A; Rouprêt, Morgan; Pycha, Armin; Fajkovic, Harun; Seitz, Christian; Karakiewicz, Pierre I; Lotan, Yair; Babjuk, Marko; de Martino, Michela; Scherr, Douglas S; Shariat, Shahrokh F.

in: J UROLOGY, Jahrgang 191, Nr. 5, 01.05.2014, S. 1238-1243.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Klatte, T, Xylinas, E, Rieken, M, Kluth, LA, Rouprêt, M, Pycha, A, Fajkovic, H, Seitz, C, Karakiewicz, PI, Lotan, Y, Babjuk, M, de Martino, M, Scherr, DS & Shariat, SF 2014, 'Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer', J UROLOGY, Jg. 191, Nr. 5, S. 1238-1243. https://doi.org/10.1016/j.juro.2013.11.106

APA

Klatte, T., Xylinas, E., Rieken, M., Kluth, L. A., Rouprêt, M., Pycha, A., Fajkovic, H., Seitz, C., Karakiewicz, P. I., Lotan, Y., Babjuk, M., de Martino, M., Scherr, D. S., & Shariat, S. F. (2014). Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. J UROLOGY, 191(5), 1238-1243. https://doi.org/10.1016/j.juro.2013.11.106

Vancouver

Klatte T, Xylinas E, Rieken M, Kluth LA, Rouprêt M, Pycha A et al. Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. J UROLOGY. 2014 Mai 1;191(5):1238-1243. https://doi.org/10.1016/j.juro.2013.11.106

Bibtex

@article{34e0dd3bf4fa41ff8103aad7a074b074,
title = "Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer",
abstract = "PURPOSE: ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma.MATERIALS AND METHODS: We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index.RESULTS: The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type O had worse recurrence and progression rates than those with A (p = 0.015 and 0.031) or B (p = 0.004 and 0.075, respectively). The concordance index of multivariable base models increased after including ABO blood type.CONCLUSIONS: In patients with nonmuscle invasive bladder urothelial carcinoma the ABO blood type may predict the outcome. Those with blood type O showed the highest recurrence and progression rates. Including ABO blood type in multivariable models increases the accuracy of standard prognostic factors. Since the ABO blood type is available for most patients, it may represent an ideal adjunctive marker to predict recurrence and progression. The biological explanation and prognostic value of this finding must be further elucidated.",
keywords = "ABO Blood-Group System, Carcinoma, Transitional Cell, Cohort Studies, Disease Progression, Humans, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Retrospective Studies, Treatment Outcome, Urinary Bladder Neoplasms",
author = "Tobias Klatte and Evanguelos Xylinas and Malte Rieken and Kluth, {Luis A} and Morgan Roupr{\^e}t and Armin Pycha and Harun Fajkovic and Christian Seitz and Karakiewicz, {Pierre I} and Yair Lotan and Marko Babjuk and {de Martino}, Michela and Scherr, {Douglas S} and Shariat, {Shahrokh F}",
note = "Copyright {\textcopyright} 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = may,
day = "1",
doi = "10.1016/j.juro.2013.11.106",
language = "English",
volume = "191",
pages = "1238--1243",
journal = "J UROLOGY",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer

AU - Klatte, Tobias

AU - Xylinas, Evanguelos

AU - Rieken, Malte

AU - Kluth, Luis A

AU - Rouprêt, Morgan

AU - Pycha, Armin

AU - Fajkovic, Harun

AU - Seitz, Christian

AU - Karakiewicz, Pierre I

AU - Lotan, Yair

AU - Babjuk, Marko

AU - de Martino, Michela

AU - Scherr, Douglas S

AU - Shariat, Shahrokh F

N1 - Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - PURPOSE: ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma.MATERIALS AND METHODS: We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index.RESULTS: The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type O had worse recurrence and progression rates than those with A (p = 0.015 and 0.031) or B (p = 0.004 and 0.075, respectively). The concordance index of multivariable base models increased after including ABO blood type.CONCLUSIONS: In patients with nonmuscle invasive bladder urothelial carcinoma the ABO blood type may predict the outcome. Those with blood type O showed the highest recurrence and progression rates. Including ABO blood type in multivariable models increases the accuracy of standard prognostic factors. Since the ABO blood type is available for most patients, it may represent an ideal adjunctive marker to predict recurrence and progression. The biological explanation and prognostic value of this finding must be further elucidated.

AB - PURPOSE: ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma.MATERIALS AND METHODS: We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index.RESULTS: The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type O had worse recurrence and progression rates than those with A (p = 0.015 and 0.031) or B (p = 0.004 and 0.075, respectively). The concordance index of multivariable base models increased after including ABO blood type.CONCLUSIONS: In patients with nonmuscle invasive bladder urothelial carcinoma the ABO blood type may predict the outcome. Those with blood type O showed the highest recurrence and progression rates. Including ABO blood type in multivariable models increases the accuracy of standard prognostic factors. Since the ABO blood type is available for most patients, it may represent an ideal adjunctive marker to predict recurrence and progression. The biological explanation and prognostic value of this finding must be further elucidated.

KW - ABO Blood-Group System

KW - Carcinoma, Transitional Cell

KW - Cohort Studies

KW - Disease Progression

KW - Humans

KW - Neoplasm Invasiveness

KW - Neoplasm Recurrence, Local

KW - Retrospective Studies

KW - Treatment Outcome

KW - Urinary Bladder Neoplasms

U2 - 10.1016/j.juro.2013.11.106

DO - 10.1016/j.juro.2013.11.106

M3 - SCORING: Journal article

C2 - 24333243

VL - 191

SP - 1238

EP - 1243

JO - J UROLOGY

JF - J UROLOGY

SN - 0022-5347

IS - 5

ER -